Question Everything. See who's reporting it.

Bharat Biotech arm partners with VeGen Bio to develop India’s first dual-target CAR-T cell therapy

Source: Times of India

The story in brief

Bharat Biotech’s CRDMO arm Nucelion Therapeutics has partnered with Hyderabad-based VeGen Bio to develop VL-2511, India’s first dual-target CAR-T cell therapy for multiple myeloma. The collaboration aims to advance VL-2511 into Phase 1 and 2 trials and commercialise it by 2028, with Nucelion handling manufacturing at its GMP facility. The partnership seeks to improve manufacturing yields and make advanced cell therapies more accessible in India.

3 outletsSee what the other 2 outlets said

NEWXFree on Android and iPhone. Open in NEWX